EMA Authorised: Praxbind (idarucizumab) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA authorised Praxbind (idarucizumab) for hemorrhage. Boehringer Ingelheim International GmbH is the marketing authorisation holder; decision date: 23/04/2026;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhage

Drugs mentioned

• Praxbind (Idarucizumab)

Snippet

Status: Authorised. Therapeutic area: Hemorrhage. MAH: Boehringer Ingelheim International GmbH. Decision date: 23/04/2026. Accelerated assessment